8-K: Sight Sciences Raises FY25 Revenue Guidance Amid Q2 Decline

Sight Sciences reported second-quarter 2025 financial results, including an 8% revenue decrease, but raised its full-year 2025 revenue guidance and reaffirmed adjusted operating expense guidance.

Summary

• Q2 2025 total revenue was $19.6 million, an 8% decrease compared to Q2 2024.
• Surgical Glaucoma revenue decreased by 5% to $19.2 million, primarily due to Medicare local coverage determinations (LCDs) restricting multiple MIGS procedures with cataract surgery.
• Dry Eye revenue decreased significantly to $0.3 million from $1.1 million in Q2 2024, as the company focuses on reimbursed market access for TearCare procedures.
• Total operating expenses decreased by 9% to $28.3 million, mainly due to lower legal expenses.
• Net loss improved slightly to $11.9 million, or $0.23 per share, compared to a net loss of $12.3 million, or $0.25 per share, in Q2 2024.
• Cash and cash equivalents stood at $101.5 million as of June 30, 2025, with $7.3 million cash used in the quarter, an improvement from $9.1 million in Q2 2024.
• Full-year 2025 revenue guidance was raised to $72.0 million to $76.0 million, while adjusted operating expense guidance was reiterated at $101.0 million to $105.0 million.
• Surgical Glaucoma ordering accounts reached an all-time high of 1,174, up 4% year-over-year.
• Published 24-month SAHARA RCT results demonstrated TearCare System durability for dry eye disease, with signs and symptoms statistically significantly better than baseline for up to 24 months.
• A cost-utility analysis showed TearCare to be cost-effective compared to cyclosporine 0.05% for MGD-associated dry eye disease, improving patient outcomes and resulting in significant cost savings.

Sentiment

Score: 7

Explanation: Despite a revenue decline in the quarter, the company demonstrated improved operational efficiency with reduced operating expenses and net loss, and a lower cash burn. The raised full-year revenue guidance and significantly reduced tariff exposure are positive indicators. Strong clinical trial results for TearCare and growth in surgical glaucoma ordering accounts also contribute to a positive outlook, although the impact of Medicare LCDs remains a headwind for Surgical Glaucoma revenue.

Positives

• Raised full-year 2025 revenue guidance to $72.0 million $76.0 million from $70.0 million $75.0 million.
• Total operating expenses decreased by 9% to $28.3 million in Q2 2025, primarily due to lower legal expenses.
• Net loss improved to $11.9 million ($0.23 per share) in Q2 2025 from $12.3 million ($0.25 per share) in Q2 2024.
• Cash used in Q2 2025 decreased to $7.3 million from $9.1 million in Q2 2024, indicating improved cash management.
• Surgical Glaucoma ordering accounts increased to an all-time high of 1,174, up 4% compared to Q2 2024.
• Published 24-month SAHARA RCT results demonstrated the durability and effectiveness of the TearCare System for dry eye disease, with sustained improvements in signs and symptoms.
• A cost-utility analysis confirmed TearCare's cost-effectiveness and patient outcome improvements compared to cyclosporine 0.05% for MGD-associated dry eye disease.
• Reduced estimated full-year 2025 tariff exposure for the Surgical Glaucoma segment to $1.0 million $1.5 million, down from $3.5 million $4.5 million.

Negatives

• Total revenue decreased by 8% to $19.6 million in Q2 2025 compared to the prior year.
• Surgical Glaucoma revenue decreased by 5% to $19.2 million, primarily due to an 11% decrease in account utilization caused by Medicare local coverage determinations (LCDs) restricting multiple MIGS procedures with cataract surgery.
• Dry Eye revenue significantly decreased from $1.1 million in Q2 2024 to $0.3 million in Q2 2025, attributed to fewer SmartLids sales as the company focuses on reimbursed market access for TearCare.
• Gross margin slightly decreased to 85% in Q2 2025 from 86% in Q2 2024, with Surgical Glaucoma gross margin at 86% (down from 88%) and Dry Eye gross margin at 38% (down from 47%).
• Cash and cash equivalents decreased to $101.5 million as of June 30, 2025, from $108.8 million as of March 31, 2025.

Risks

• Incremental or unanticipated changes in tariff policies or rates impacting products or the medical device industry.
• Changes to reimbursement coverage, payment decisions, or reimbursement rates for products.
• Changes to product pricing or market share resulting from the evolving competitive landscape.
• Unforeseen changes in regulatory requirements.
• Disruptions to or increased costs associated with the supply chain, including as a result of having a limited number of suppliers.
• Risks and uncertainties identified under the caption 'Risk Factors' in annual and quarterly reports with the SEC.

Future Outlook

The company raised its full-year 2025 revenue guidance to $72.0 million to $76.0 million, representing a 5% to 10% decline compared to full-year 2024 revenue, an increase from the prior guidance of $70.0 million to $75.0 million. Adjusted operating expenses guidance for full-year 2025 was reiterated at $101.0 million to $105.0 million, representing a 0% to 4% increase compared to full-year 2024. The company expects its Surgical Glaucoma segment's unmitigated tariff exposure to increase cost of goods sold by $1.0 million to $1.5 million for full-year 2025, a reduction from the prior estimate of $3.5 million to $4.5 million. Management expresses confidence in delivering long-term value and elevating the standard of care for glaucoma and dry eye disease management, driven by strong execution, growing momentum, and strategic initiatives.

Management Comments

• "Our second-quarter results reflect strong execution and growing momentum, with positive trends including sequential growth in both surgical glaucoma ordering accounts and procedural utilization that mark meaningful progress as we strengthen our position as the market leader in implant-free MIGS."
• "Our focus has been on equipping interventional eyecare providers with innovative technologies that enhance patient outcomes."
• "As we enter the second half of 2025, these developments reinforce our confidence in our ability to deliver long-term value and elevate the standard of care for glaucoma and dry eye disease management."

Industry Context

The eyecare technology industry, particularly in glaucoma and dry eye disease, is undergoing a shift towards interventional solutions over medication management. Sight Sciences operates in two large, underserved markets. The company's Surgical Glaucoma segment is impacted by recent Medicare local coverage determinations (LCDs) that restrict coverage for multiple MIGS procedures when performed with cataract surgery, leading to a decline in account utilization. Despite this, the company is seeing growth in ordering accounts, suggesting underlying demand for its implant-free MIGS technologies. In the Dry Eye segment, the focus on achieving reimbursed market access for the TearCare System reflects a broader industry trend towards establishing clear reimbursement pathways for innovative, non-invasive treatments for meibomian gland disease (MGD), which is a significant cause of dry eye. The publication of positive clinical trial results (SAHARA RCT) and cost-utility analyses for TearCare positions it favorably against conventional treatments like cyclosporine.

Comparison to Industry Standards

• TearCare has been proven clinically superior to Restasis/cyclosporine in Tear Breakup Time (TBUT) improvement at 6 months in the SAHARA RCT, and non-inferior in OSDI.
• A cost-utility analysis demonstrated that TearCare resulted in significant cost savings compared to cyclosporine 0.05% (CsA) for the treatment of moderate to severe meibomian gland disease (MGD) associated dry eye disease.
• The OMNI Surgical System is highlighted as the most comprehensive implant-free Minimally Invasive Glaucoma Surgery (MIGS) technology, with robust clinical evidence from trials like ROMEO and GEMINI, and registry results from AAO IRIS Registry.
• The company's OMNI technology addresses all six MIGS POAG categories, allowing surgeons to customize treatment, which is a key differentiator in the market.

Stakeholder Impact

• Shareholders: Potential for increased value due to raised revenue guidance, improved operational efficiency, and positive clinical developments, despite current revenue declines.
• Patients: Improved treatment options for glaucoma and dry eye disease through OMNI and TearCare, with demonstrated durability and cost-effectiveness.
• Eyecare Providers: Access to innovative, interventional technologies that enhance patient outcomes and offer comprehensive treatment options for POAG and MGD.
• Employees: Continued focus on R&D, clinical, and commercial infrastructure suggests ongoing investment in the business.
• Medicare/Payers: Impacted by Medicare LCDs restricting certain MIGS procedures, but also potential for cost savings with TearCare.

Next Steps

• Strengthen position as market leader in implant-free MIGS.
• Deliver long-term value and elevate the standard of care for glaucoma and dry eye disease management.
• Achieve reimbursed market access for TearCare procedures.
• Expand OMNI utilization by certifying new surgeons and gaining share in combination cataract segment.
• Develop the standalone pseudophakic MIGS segment.
• Generate additional clinical evidence for OMNI and TearCare.
• Enhance coverage and equitable reimbursement for OMNI.
• Develop international markets for OMNI.
• Generate eyecare provider engagement and pursue coverage and equitable reimbursement for TearCare.
• Grow the commercial team and expand adoption and usage of TearCare.
• Continue development of pipeline products for Surgical Glaucoma (Implantable Canalicular Scaffold, Suprachoroidal Implant, Sustained Release Pharmaceutical).

Key Dates

Recommendation

While Sight Sciences demonstrated improved operational efficiency, reduced cash burn, and raised its full-year revenue guidance, the core revenue decline in Q2 2025, particularly in Surgical Glaucoma due to Medicare LCDs, remains a significant headwind. The Dry Eye segment's revenue also saw a substantial decrease as the company focuses on reimbursement. The positive clinical data for TearCare and the reduction in tariff exposure are encouraging, but the company is still navigating market access challenges and competitive pressures. Given the mixed results and ongoing strategic shifts, a 'hold' recommendation is appropriate, suggesting investors monitor the execution of market access strategies for TearCare and the adaptation to Medicare reimbursement changes for MIGS.

Keywords

Sight Sciences, SGHT, Ophthalmology, Glaucoma, Dry Eye Disease, MIGS, OMNI Surgical System, TearCare System, Financial Results, Revenue Guidance, SEC Filing, Medical Devices, Eyecare Technology, SAHARA RCT, Medicare LCDs, Meibomian Gland Dysfunction